Physiomics plc announced that it has been awarded a substantial new contract by an existing large pharma client. The project involves Pharmacokinetic-Pharmacodynamic (PKPD) modelling in the field of DNA damage/repair field and will help inform clinical dose and scheduling decisions. The value of the project is £178,000 and it is anticipated that it will be completed over the course of the next six months.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.55 GBX | +3.33% | 0.00% | -3.12% |
Mar. 18 | Transcript : Physiomics Plc, H1 2024 Earnings Call, Mar 18, 2024 | |
Mar. 18 | Physiomics celebrates "substantial" contract with old client | AN |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-3.12% | 2.55M | |
-5.82% | 130B | |
+7.97% | 69.31B | |
-17.12% | 37.79B | |
+9.36% | 36.04B | |
-9.89% | 27.88B | |
-12.29% | 16.12B | |
+7.80% | 14.74B | |
+11.64% | 10.56B | |
-26.24% | 4.74B |
- Stock Market
- Equities
- PYC Stock
- News Physiomics Plc
- Physiomics plc Wins Contract by an Existing Pharma Client